Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non‐small cell lung cancer patients

Abstract Growing efforts are being invested in investigating various molecular approaches to detect minimal residual disease (MRD) and predict disease recurrence. In our study, we investigated the utility of parallel longitudinal analysis of mutation and DNA methylation profiles for predicting MRD i...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hang Li, Ze‐Lin Ma, Bin Li, Yun‐jian Pan, Jia‐Qing Xiang, Ya‐Wei Zhang, Yi‐Hua Sun, Ting Hou, Analyn Lizaso, Yan Chen, Xi Li, Hong Hu
Formato: article
Lenguaje:EN
Publicado: Wiley 2021
Materias:
Acceso en línea:https://doaj.org/article/f9cf44dbf7b144dd826ad9e7c78bdd6b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f9cf44dbf7b144dd826ad9e7c78bdd6b
record_format dspace
spelling oai:doaj.org-article:f9cf44dbf7b144dd826ad9e7c78bdd6b2021-12-01T04:49:15ZPotential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non‐small cell lung cancer patients2045-763410.1002/cam4.4339https://doaj.org/article/f9cf44dbf7b144dd826ad9e7c78bdd6b2021-12-01T00:00:00Zhttps://doi.org/10.1002/cam4.4339https://doaj.org/toc/2045-7634Abstract Growing efforts are being invested in investigating various molecular approaches to detect minimal residual disease (MRD) and predict disease recurrence. In our study, we investigated the utility of parallel longitudinal analysis of mutation and DNA methylation profiles for predicting MRD in postoperative non‐small‐cell lung cancer (NSCLC) patients. Tumor tissues and longitudinal blood samples were obtained from 65 patients with resected stage IA‐IIIB NSCLC. Somatic mutation and DNA methylation profiling were performed using ultra‐deep targeted sequencing and targeted bisulfite sequencing, respectively. Dynamic changes in plasma‐based mutation and tumor‐informed methylation profiles, reflected as MRD score, were observed from before surgery (baseline) to postoperative follow‐up, reflecting the decrease in tumor burden of the patients with resected NSCLC. Mutations were detected from plasma samples in 63% of the patients at baseline, which significantly reduced to 23‐25% during post‐operative follow‐ups. MRD score positive rate was 95.7% at baseline, which reduced to 74% at the first and 70% at the second follow‐up. Among the 5 relapsed patients with parallel longitudinal analysis of mutation and methylation profile, elevated MRD score was observed at follow‐up between 0.5‐7 months prior to radiologic recurrence for all 5 patients. Of them, 4 patients also had concomitant increase in allelic fraction of mutations in at least 1 follow‐up time point, but one patient had no mutation detected throughout all follow‐ups. Our results demonstrate that longitudinal profiling of mutation and DNA methylation may have potential for detecting MRD and predicting recurrence in postoperative NSCLC patients.Hang LiZe‐Lin MaBin LiYun‐jian PanJia‐Qing XiangYa‐Wei ZhangYi‐Hua SunTing HouAnalyn LizasoYan ChenXi LiHong HuWileyarticleDNA methylationmolecular residual diseaseprognostic biomarkerrecurrenceresected NSCLCNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Medicine, Vol 10, Iss 23, Pp 8377-8386 (2021)
institution DOAJ
collection DOAJ
language EN
topic DNA methylation
molecular residual disease
prognostic biomarker
recurrence
resected NSCLC
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle DNA methylation
molecular residual disease
prognostic biomarker
recurrence
resected NSCLC
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Hang Li
Ze‐Lin Ma
Bin Li
Yun‐jian Pan
Jia‐Qing Xiang
Ya‐Wei Zhang
Yi‐Hua Sun
Ting Hou
Analyn Lizaso
Yan Chen
Xi Li
Hong Hu
Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non‐small cell lung cancer patients
description Abstract Growing efforts are being invested in investigating various molecular approaches to detect minimal residual disease (MRD) and predict disease recurrence. In our study, we investigated the utility of parallel longitudinal analysis of mutation and DNA methylation profiles for predicting MRD in postoperative non‐small‐cell lung cancer (NSCLC) patients. Tumor tissues and longitudinal blood samples were obtained from 65 patients with resected stage IA‐IIIB NSCLC. Somatic mutation and DNA methylation profiling were performed using ultra‐deep targeted sequencing and targeted bisulfite sequencing, respectively. Dynamic changes in plasma‐based mutation and tumor‐informed methylation profiles, reflected as MRD score, were observed from before surgery (baseline) to postoperative follow‐up, reflecting the decrease in tumor burden of the patients with resected NSCLC. Mutations were detected from plasma samples in 63% of the patients at baseline, which significantly reduced to 23‐25% during post‐operative follow‐ups. MRD score positive rate was 95.7% at baseline, which reduced to 74% at the first and 70% at the second follow‐up. Among the 5 relapsed patients with parallel longitudinal analysis of mutation and methylation profile, elevated MRD score was observed at follow‐up between 0.5‐7 months prior to radiologic recurrence for all 5 patients. Of them, 4 patients also had concomitant increase in allelic fraction of mutations in at least 1 follow‐up time point, but one patient had no mutation detected throughout all follow‐ups. Our results demonstrate that longitudinal profiling of mutation and DNA methylation may have potential for detecting MRD and predicting recurrence in postoperative NSCLC patients.
format article
author Hang Li
Ze‐Lin Ma
Bin Li
Yun‐jian Pan
Jia‐Qing Xiang
Ya‐Wei Zhang
Yi‐Hua Sun
Ting Hou
Analyn Lizaso
Yan Chen
Xi Li
Hong Hu
author_facet Hang Li
Ze‐Lin Ma
Bin Li
Yun‐jian Pan
Jia‐Qing Xiang
Ya‐Wei Zhang
Yi‐Hua Sun
Ting Hou
Analyn Lizaso
Yan Chen
Xi Li
Hong Hu
author_sort Hang Li
title Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non‐small cell lung cancer patients
title_short Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non‐small cell lung cancer patients
title_full Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non‐small cell lung cancer patients
title_fullStr Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non‐small cell lung cancer patients
title_full_unstemmed Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non‐small cell lung cancer patients
title_sort potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non‐small cell lung cancer patients
publisher Wiley
publishDate 2021
url https://doaj.org/article/f9cf44dbf7b144dd826ad9e7c78bdd6b
work_keys_str_mv AT hangli potentialutilityoflongitudinalsomaticmutationandmethylationprofilingforpredictingmolecularresidualdiseaseinpostoperativenonsmallcelllungcancerpatients
AT zelinma potentialutilityoflongitudinalsomaticmutationandmethylationprofilingforpredictingmolecularresidualdiseaseinpostoperativenonsmallcelllungcancerpatients
AT binli potentialutilityoflongitudinalsomaticmutationandmethylationprofilingforpredictingmolecularresidualdiseaseinpostoperativenonsmallcelllungcancerpatients
AT yunjianpan potentialutilityoflongitudinalsomaticmutationandmethylationprofilingforpredictingmolecularresidualdiseaseinpostoperativenonsmallcelllungcancerpatients
AT jiaqingxiang potentialutilityoflongitudinalsomaticmutationandmethylationprofilingforpredictingmolecularresidualdiseaseinpostoperativenonsmallcelllungcancerpatients
AT yaweizhang potentialutilityoflongitudinalsomaticmutationandmethylationprofilingforpredictingmolecularresidualdiseaseinpostoperativenonsmallcelllungcancerpatients
AT yihuasun potentialutilityoflongitudinalsomaticmutationandmethylationprofilingforpredictingmolecularresidualdiseaseinpostoperativenonsmallcelllungcancerpatients
AT tinghou potentialutilityoflongitudinalsomaticmutationandmethylationprofilingforpredictingmolecularresidualdiseaseinpostoperativenonsmallcelllungcancerpatients
AT analynlizaso potentialutilityoflongitudinalsomaticmutationandmethylationprofilingforpredictingmolecularresidualdiseaseinpostoperativenonsmallcelllungcancerpatients
AT yanchen potentialutilityoflongitudinalsomaticmutationandmethylationprofilingforpredictingmolecularresidualdiseaseinpostoperativenonsmallcelllungcancerpatients
AT xili potentialutilityoflongitudinalsomaticmutationandmethylationprofilingforpredictingmolecularresidualdiseaseinpostoperativenonsmallcelllungcancerpatients
AT honghu potentialutilityoflongitudinalsomaticmutationandmethylationprofilingforpredictingmolecularresidualdiseaseinpostoperativenonsmallcelllungcancerpatients
_version_ 1718405761691811840